Your browser doesn't support javascript.
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer, Avishay; Angel, Yoel; Marudi, Or; Zeltser, David; Saiag, Esther; Goldshmidt, Hanoch; Goldiner, Ilana; Stark, Moshe; Halutz, Ora; Gamzu, Ronni; Slobodkin, Marina; Amrami, Nadav; Feigin, Eugene; Elbaz, Meital; Furman, Moran; Bronstein, Yotam; Chikly, Amanda; Eshkol, Anna; Furer, Victoria; Mayer, Talia; Meijer, Suzy; Melloul, Ariel; Mizrahi, Michal; Yakubovsky, Michal; Rosenberg, Dana; Safir, Ari; Spitzer, Liron; Taleb, Eyal; Elkayam, Ori; Silberman, Adi; Eviatar, Tali; Elalouf, Ofir; Levinson, Tal; Pozyuchenko, Katia; Itzhaki-Alfia, Ayelet; Sprecher, Eli; Ben-Ami, Ronen; Henig, Oryan.
  • Spitzer A; Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Angel Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Marudi O; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Zeltser D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Saiag E; Department of Anesthesia, Pain Management and Intensive Care, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Goldshmidt H; Department of Physician Affairs, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Goldiner I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Stark M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Halutz O; Department of Emergency Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Gamzu R; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Slobodkin M; Department of Information Systems and Operations, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Amrami N; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Feigin E; Department of Clinical Laboratories, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Elbaz M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Furman M; Department of Clinical Laboratories, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Bronstein Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Chikly A; Department of Clinical Laboratories, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Eshkol A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Furer V; Department of Clinical Laboratories, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Mayer T; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Meijer S; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Melloul A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Mizrahi M; Department of Internal Medicine "D," Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Yakubovsky M; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Rosenberg D; Department of Internal Medicine "D," Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Safir A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Spitzer L; Department of Internal Medicine "D," Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Taleb E; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Elkayam O; Department of Infectious Diseases and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Silberman A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Eviatar T; Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Elalouf O; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Levinson T; Department of Internal Medicine "D," Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Pozyuchenko K; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Itzhaki-Alfia A; Department of Infectious Diseases and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Sprecher E; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ben-Ami R; Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Henig O; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
JAMA ; 327(4): 341-349, 2022 01 25.
Article in English | MEDLINE | ID: covidwho-1838085
ABSTRACT
Importance Administration of a BNT162b2 booster dose (Pfizer-BioNTech) to fully vaccinated individuals aged 60 years and older was significantly associated with lower risk of SARS-CoV-2 infection and severe illness. Data are lacking on the effectiveness of booster doses for younger individuals and health care workers.

Objective:

To estimate the association of a BNT162b2 booster dose with SARS-CoV-2 infections among health care workers who were previously vaccinated with a 2-dose series of BNT162b2. Design, Setting, and

Participants:

This was a prospective cohort study conducted at a tertiary medical center in Tel Aviv, Israel. The study cohort included 1928 immunocompetent health care workers who were previously vaccinated with a 2-dose series of BNT162b2, and had enrolled between August 8 and 19, 2021, with final follow-up reported through September 20, 2021. Screening for SARS-CoV-2 infection was performed every 14 days. Anti-spike protein receptor binding domain IgG titers were determined at baseline and 1 month after enrollment. Cox regression with time-dependent analysis was used to estimate hazard ratios of SARS-CoV-2 infection between booster-immunized status and 2-dose vaccinated (booster-nonimmunized) status. Exposures Vaccination with a booster dose of BNT162b2 vaccine. Main Outcomes and

Measures:

The primary outcome was SARS-CoV-2 infection, as confirmed by reverse transcriptase-polymerase chain reaction.

Results:

Among 1928 participants, the median age was 44 years (IQR, 36-52 years) and 1381 were women (71.6%). Participants completed the 2-dose vaccination series a median of 210 days (IQR, 205-213 days) before study enrollment. A total of 1650 participants (85.6%) received the booster dose. During a median follow-up of 39 days (IQR, 35-41 days), SARS-CoV-2 infection occurred in 44 participants (incidence rate, 60.2 per 100 000 person-days); 31 (70.5%) were symptomatic. Five SARS-CoV-2 infections occurred in booster-immunized participants and 39 in booster-nonimmunized participants (incidence rate, 12.8 vs 116 per 100 000 person-days, respectively). In a time-dependent Cox regression analysis, the adjusted hazard ratio of SARS-CoV-2 infection for booster-immunized vs booster-nonimmunized participants was 0.07 (95% CI, 0.02-0.20). Conclusions and Relevance Among health care workers at a single center in Israel who were previously vaccinated with a 2-dose series of BNT162b2, administration of a booster dose compared with not receiving one was associated with a significantly lower rate of SARS-CoV-2 infection over a median of 39 days of follow-up. Ongoing surveillance is required to assess durability of the findings.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Health Personnel / COVID-19 Vaccines / COVID-19 / Vaccine Efficacy / BNT162 Vaccine / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: JAMA Year: 2022 Document Type: Article Affiliation country: Jama.2021.23641

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Health Personnel / COVID-19 Vaccines / COVID-19 / Vaccine Efficacy / BNT162 Vaccine / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: JAMA Year: 2022 Document Type: Article Affiliation country: Jama.2021.23641